---
title: Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
nct_id: NCT04390360
overall_status: UNKNOWN
phase: NA
sponsor: Laval University
study_type: INTERVENTIONAL
primary_condition: ARDS, Human
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04390360.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04390360"
ct_last_update_post_date: 2023-03-10
last_seen_at: "2026-05-12T06:09:39.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction

**Official Title:** Development and Evaluation of Smartphone App for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction on Physiologic Parameter Based on the Smartphone App

**NCT ID:** [NCT04390360](https://clinicaltrials.gov/study/NCT04390360)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Laval University
- **Conditions:** ARDS, Human, Mechanical Ventilation Complication, Humidifier Lung
- **Start Date:** 2019-11-01
- **Completion Date:** 2024-06-30
- **CT.gov Last Update:** 2023-03-10

## Brief Summary

Clinical evaluation of a new educative tools (Smartphone application) based on impact of instrumental dead space reduction after initiation of protective ventilation during mechanical ventilation.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \> 18 years old
* Mechanical ventilation (control,assist control or SIMV mode)
* haemodynamic stability (vasopressor \< 0.2 ug/kg/min)
* no prone position schedule in the next 2 hours following procedure inclusion
* presence of an Arterial catheter

Exclusion Criteria:

* ECMO or anticipate ECMO
* body temperature \< 36.0 for post operative patient (cardiac surgery)
```

## Arms

- **Protective ventilation with HME** (OTHER) — Protective ventilation + HME
- **Protective ventilation with Heated humidifier** (OTHER) — Protective ventilation + HH
- **Implementation of protective ventilation** (OTHER) — Protective ventilation implementation
- **Tidal Volume reduction** (OTHER) — Tidal volume reduction

## Interventions

- **Protective ventilation implementation** (PROCEDURE) — In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
- **Protective ventilation with HME** (PROCEDURE) — In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
- **Protective ventilation with Heated humidifier** (PROCEDURE) — In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
- **Tidal Volume reduction** (PROCEDURE) — n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition

## Primary Outcomes

- **PaCO2 Variation** _(time frame: 60 minutes post intervention)_ — The primary outcome is to evaluate the PaCO2 variation at the end of condition 2 (after 30 minutes with protective ventilation+ HME) and condition 4 (30 minutes after Tidal volume reduction + Heater humidifier).

Variation \<= 10% of PaCO2
- **PaCO2 Variation** _(time frame: 120 minutes post intervention)_ — The primary outcome is to evaluate the PaCO2 variation at the end of condition 2 (after 30 minutes with protective ventilation+ HME) and condition 4 (30 minutes after Tidal volume reduction + Heater humidifier).

Variation \<= 10% of PaCO2

## Secondary Outcomes

- **Correlation between PCO2 variation and alveolar ventilation variation** _(time frame: 60 and 90 minutes post intervention)_
- **Hemodynamic impact vs pH** _(time frame: Baseline, 30, 60, 90 and 120 minutes post intervention)_
- **Hemodynamic impact vs pH** _(time frame: Baseline, 30, 60, 90 and 120 minutes post intervention)_
- **Hemodynamic impact vs pH** _(time frame: Baseline, 30, 60, 90 and 120 minutes post intervention)_

## Locations (1)

- Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institut universitaire de cardiologie et de pneumologie de québec - université laval|québec||canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04390360.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04390360*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*